Evotec
Kate Walton has over six years of experience in quality control and analytical chemistry, currently serving as a QC Analyst III at Evotec since February 2018, where progression through roles from QC Analyst I to III has been achieved. Prior experience includes working as an Analytical Scientist at Mylan from July 2017 to February 2018, and earlier as an Analytical Scientist during a year in industry from July 2015 to August 2016. In these roles, Kate Walton specialized in laboratory analysis of dry powder inhalation products, managed UPLC systems, and prepared analytical standards, all while adhering to Good Laboratory Practice (GLP) and Good Documentation Practice (GDP). Kate Walton holds a Master’s Degree in Forensic and Analytical Chemistry from the University of Strathclyde, completed in 2017.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.